JP2010502649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502649A5 JP2010502649A5 JP2009526935A JP2009526935A JP2010502649A5 JP 2010502649 A5 JP2010502649 A5 JP 2010502649A5 JP 2009526935 A JP2009526935 A JP 2009526935A JP 2009526935 A JP2009526935 A JP 2009526935A JP 2010502649 A5 JP2010502649 A5 JP 2010502649A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor agonist
- partial
- administered
- combination
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 64
- 239000000018 receptor agonist Substances 0.000 claims description 57
- 229940044601 receptor agonist Drugs 0.000 claims description 57
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 32
- 229960001948 caffeine Drugs 0.000 claims description 32
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 claims description 15
- 229960003614 regadenoson Drugs 0.000 claims description 15
- 238000003384 imaging method Methods 0.000 claims description 7
- 230000002107 myocardial effect Effects 0.000 claims description 7
- 230000017531 blood circulation Effects 0.000 claims description 6
- 230000010412 perfusion Effects 0.000 claims description 6
- 229940124549 vasodilator Drugs 0.000 claims description 6
- 239000003071 vasodilator agent Substances 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000004165 myocardium Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 description 30
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84184206P | 2006-09-01 | 2006-09-01 | |
| PCT/US2007/077410 WO2008028140A1 (en) | 2006-09-01 | 2007-08-31 | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502649A JP2010502649A (ja) | 2010-01-28 |
| JP2010502649A5 true JP2010502649A5 (enExample) | 2011-09-29 |
Family
ID=38935783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526935A Pending JP2010502649A (ja) | 2006-09-01 | 2007-08-31 | 心筋層画像化法中の患者の耐性を増加させるための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080213165A1 (enExample) |
| EP (1) | EP2056834B1 (enExample) |
| JP (1) | JP2010502649A (enExample) |
| KR (1) | KR20090047499A (enExample) |
| CN (1) | CN101511366B (enExample) |
| AU (1) | AU2007289037A1 (enExample) |
| BR (1) | BRPI0716174A2 (enExample) |
| CA (1) | CA2662278C (enExample) |
| IL (1) | IL197267A0 (enExample) |
| MX (1) | MX2009002299A (enExample) |
| RU (1) | RU2459626C2 (enExample) |
| WO (1) | WO2008028140A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| CA2439222C (en) * | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| SI2801354T1 (sl) | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| CA2583185A1 (en) * | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
| PL1989214T3 (pl) | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
| CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| JP2011502101A (ja) * | 2006-09-29 | 2011-01-20 | ギリアード・パロ・アルト・インコーポレイテッド | 肺疾患の病歴を有する患者における心筋画像化法 |
| EP2099360A2 (en) * | 2007-01-03 | 2009-09-16 | CV Therapeutics Inc. | Myocardial perfusion imaging |
| EP2344145A1 (en) * | 2008-09-29 | 2011-07-20 | Gilead Sciences, Inc. | Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods |
| GB201100137D0 (en) | 2011-01-06 | 2011-02-23 | Davies Helen C S | Apparatus and method of assessing a narrowing in a fluid tube |
| US9339348B2 (en) | 2011-08-20 | 2016-05-17 | Imperial Colege of Science, Technology and Medicine | Devices, systems, and methods for assessing a vessel |
| WO2013028612A2 (en) | 2011-08-20 | 2013-02-28 | Volcano Corporation | Devices, systems, and methods for visually depicting a vessel and evaluating treatment options |
| TW201341367A (zh) | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | ３，５－二胺基吡唑激酶抑制劑 |
| EP2789624B1 (en) * | 2013-04-11 | 2020-09-23 | AMRI Italy S.r.l. | Stable solid forms of regadenoson |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| HUE049801T2 (hu) | 2014-12-23 | 2020-10-28 | Sma Therapeutics Inc | 3,5-diaminopirazol kináz inhibitorok |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
| US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
| SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
| JPS6299395A (ja) * | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | ２−アルキニルアデノシンおよび抗高血圧剤 |
| US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| DE68916036T2 (de) * | 1988-11-15 | 1994-09-29 | Toa Eiyo Ltd | Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen. |
| KR920700218A (ko) * | 1989-06-20 | 1992-02-19 | 원본미기재 | 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체 |
| US5032252A (en) * | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| JP2740362B2 (ja) * | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | 安定な固体状２‐オクチニルアデノシンおよびその製造法 |
| US5516894A (en) * | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| EP0601322A3 (en) * | 1992-10-27 | 1994-10-12 | Nippon Zoki Pharmaceutical Co | Adenosine deaminase inhibitor. |
| CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
| DE69526822T2 (de) * | 1994-02-23 | 2003-01-23 | Kyowa Hakko Kogyo K.K., Tokio/Tokyo | Xanthin-derivate |
| US5704491A (en) * | 1995-07-21 | 1998-01-06 | Cummins-Allison Corp. | Method and apparatus for discriminating and counting documents |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| US6448235B1 (en) * | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
| US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US5548237A (en) * | 1995-03-10 | 1996-08-20 | International Business Machines Corporation | Process tolerant delay circuit |
| US5854081A (en) * | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
| US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
| US6026317A (en) * | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6368573B1 (en) * | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| CA2439222C (en) * | 2000-02-23 | 2009-07-14 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
| US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
| US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
| US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
| US7109203B2 (en) * | 2001-05-14 | 2006-09-19 | Novartis Ag | Sulfonamide derivatives |
| KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제 |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| BR0215202A (pt) * | 2001-12-20 | 2004-10-13 | Osi Pharm Inc | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso |
| WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| AU2005295654B2 (en) * | 2004-10-15 | 2011-04-14 | Gilead Sciences, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| CA2583185A1 (en) * | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
| BRPI0606662A2 (pt) * | 2005-01-12 | 2010-02-09 | King Pharmaceuticals Res & Dev | métodos para diagnosticar a disfunção miocárdica, a doença da artéria coronária, a disfunção ventricular causada pela doença da artéria coronária, anormalidades de perfusão, para diagnosticar a presença e avaliar a severidade da doença da artéria coronária e a severidade da disfunção ventricular e a disfunção miocárdica, e, kit |
| PL1989214T3 (pl) * | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
| CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| JP2011502101A (ja) * | 2006-09-29 | 2011-01-20 | ギリアード・パロ・アルト・インコーポレイテッド | 肺疾患の病歴を有する患者における心筋画像化法 |
| EP2099360A2 (en) * | 2007-01-03 | 2009-09-16 | CV Therapeutics Inc. | Myocardial perfusion imaging |
| EP2344145A1 (en) * | 2008-09-29 | 2011-07-20 | Gilead Sciences, Inc. | Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods |
-
2007
- 2007-08-31 JP JP2009526935A patent/JP2010502649A/ja active Pending
- 2007-08-31 US US11/848,743 patent/US20080213165A1/en not_active Abandoned
- 2007-08-31 WO PCT/US2007/077410 patent/WO2008028140A1/en not_active Ceased
- 2007-08-31 CA CA2662278A patent/CA2662278C/en active Active
- 2007-08-31 EP EP07841736A patent/EP2056834B1/en active Active
- 2007-08-31 CN CN2007800319956A patent/CN101511366B/zh not_active Expired - Fee Related
- 2007-08-31 BR BRPI0716174-3A2A patent/BRPI0716174A2/pt not_active IP Right Cessation
- 2007-08-31 RU RU2009106862/15A patent/RU2459626C2/ru not_active IP Right Cessation
- 2007-08-31 MX MX2009002299A patent/MX2009002299A/es not_active Application Discontinuation
- 2007-08-31 AU AU2007289037A patent/AU2007289037A1/en not_active Abandoned
- 2007-08-31 KR KR1020097004186A patent/KR20090047499A/ko not_active Ceased
-
2009
- 2009-02-26 IL IL197267A patent/IL197267A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2662278A1 (en) | Methods and compositions for increasing patient tolerability during myocardial imaging methods | |
| JP2010515081A5 (enExample) | ||
| JP5592262B2 (ja) | 肝細胞の増殖を誘導する方法及びその使用 | |
| JP2011502101A5 (enExample) | ||
| JP2018519340A5 (enExample) | ||
| JP2005538190A5 (enExample) | ||
| CN108472275A (zh) | 治疗缺血性中风的组合物及方法 | |
| CA2492855A1 (en) | Myocardial perfusion imaging using a2a receptor agonists | |
| JP2012229273A (ja) | ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法 | |
| US20150018299A1 (en) | Treatment of liver conditions | |
| JP2022510014A (ja) | Ｃ型肝炎ウイルスの治療のための高活性な合剤 | |
| RU2007114908A (ru) | Применение агонистов аденозиновых рецепторов a2a | |
| JP6990934B2 (ja) | 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド | |
| CA2893427A1 (en) | Methods for treating gi tract disorders | |
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| KR102205368B1 (ko) | Fxr 작용제의 신규 요법 | |
| Rajani et al. | Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion | |
| JP2011506607A5 (enExample) | ||
| JP2004506684A (ja) | 肝細胞への薬物送達及びフラビウイルス感染症の治療の方法 | |
| CN110996955A (zh) | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| WO2022251594A1 (en) | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs | |
| Bryson et al. | Absorption, metabolism, and excretion of (3H)‐ospemifene following a single oral dose to post‐menopausal women | |
| JP2014144969A (ja) | 肝細胞の増殖を誘導する方法及びその使用 | |
| Nakatsuka et al. | A CYP3A4 inhibitor increased the effect of cabergoline in the treatment of Parkinson's disease |